

PATENT COOPERATION TREATY

PCT

From the INTERNATIONAL BUREAU

NOTIFICATION OF THE RECORDING
OF A CHANGE(PCT Rule 92bis.1 and
Administrative Instructions, Section 422)

To:

RIGAUT, Kathleen, D.
Saul, Ewing, Remick & Saul, LLP
Centre Square West
1500 Market Street, 38th Floor
Philadelphia, PA 19102-2186
ETATS-UNIS D'AMERIQUE

Date of mailing (day/month/year)

18 July 2000 (18.07.00)

Applicant's or agent's file reference

UMDNJ - 9808

IMPORTANT NOTIFICATION

International application No.

PCT/US99/25477

International filing date (day/month/year)

29 October 1999 (29.10.99)

1. The following indications appeared on record concerning:

☐

the applicant

☐

the inventor

☒

the agent

☐

the common representative

Name and Address

RIGAUT, Kathleen, D.
Dann, Dorfman, Herrell and Skillman
Suite 720
1601 Market Street
Philadelphia, PA 19103-2307
United States of America

State of Nationality

State of Residence

Telephone No.

(215) 563-4100

Facsimile No.

(215) 563-4044

Teleprinter No.

2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:

☐

the person

☐

the name

☒

the address

☐

the nationality

☐

the residence

Name and Address

RIGAUT, Kathleen, D.
Saul, Ewing, Remick & Saul, LLP
Centre Square West
1500 Market Street, 38th Floor
Philadelphia, PA 19102-2186
United States of America

State of Nationality

State of Residence

Telephone No.

215 972 8386

Facsimile No.

215 972 2292

Teleprinter No.

3. Further observations, if necessary:

4. A copy of this notification has been sent to:

☒

the receiving Office

☐

the International Searching Authority

☒

the International Preliminary Examining Authority

☐

the designated Offices concerned

☒

the elected Offices concerned

☐

other:

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Authorized officer

Eugénia Santos

Facsimile No.: (41-22) 740.14.35

Telephone No.: (41-22) 338.83.38

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/85, 15/86, 15/11	A1	(11) International Publication Number: WO 00/26393 (43) International Publication Date: 11 May 2000 (11.05.00)
(21) International Application Number: PCT/US99/25477 (22) International Filing Date: 29 October 1999 (29.10.99) (30) Priority Data: 60/106,533 31 October 1998 (31.10.98) US (71) Applicant (for all designated States except US): UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY [US/US]; 30 Bergen Street, Newark, NJ 07107 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): RON, Yacov [US/US]; 24 Yorktown Road, East Brunswick, NJ 08816 (US). DOUGHERTY, Joseph, P. [US/US]; 18 Wolf's Farm, Hampton, NJ 08827 (US). CHEN, Chiann-Chyi [-/US]; 49 Marvin Lane, Piscataway, NJ 08854 (US). (74) Agents: RIGAUT, Kathleen, D. et al.; Dann, Dorfman, Herrell and Skillman, Suite 720, 1601 Market Street, Philadelphia, PA 19103-2307 (US).		(81) Designated States: AU, CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: A MYELOID PRECURSOR CELL USEFUL FOR GENE THERAPY AND FOR MODULATION OF IMMUNE RESPONSES		
(57) Abstract A long-lived, myeloid-committed stem cell population is disclosed. Also disclosed are methods and compositions for targeting this population with retrovirus vectors in gene therapy protocols for correcting congenital disorders of myeloid system and for potentiating immune responses to defined tumor and viral antigens.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/25477**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) : C12N 15/85, 15/86, 15/11

US CL : 435/325; 536/23.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/325; 536/23.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

STN, Medline, WEST

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CHEN et al. Long-Term Contribution to the Myeloid Compartment by Lineage-Committed Stem Cells. Blood. 01 November 1998, Vol. 92, No. 9, pages 3210-3217, entire document.	1-19
Y	HUMEAU et al. Successful Reconstitution of Human Hematopoiesis in the SCID-hu Mouse by Genetically Modified, Highly Enriched Progenitors Isolated From Fetal Liver. Blood. 01 November 1997, Vol. 90, No. 9 pages 3496-3506, figure 2 and figure 5.	1-3
Y	PERSONS et al. Retroviral-Mediated Transfer of the Green Fluorescent Protein Gene Into Murine Hematopoietic Cells Facilitates Scoring and Selection of Transduced Progenitors In Vitro and Identification of Genetically Modified Cells in Vivo. Blood. 01 September 1997, Vol. 90, No. 5, pages 1777-1786, figure 1.	6-7
X	US 5,502,176 A (TENEN et al.) 26 March 1996, entire document.	3-15

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
B earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

11 JANUARY 2000

Date of mailing of the international search report

08 FEB 2000

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

JOSEPH T. WOITACH

Telephone No. (703) 308-0196

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

REC'D 09 MAR 2001

WIPO

PCT

Applicant's or agent's file reference UMDNT-98-08	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/US99/25477	International filing date (day/month/year) 29 OCTOBER 1999	Priority date (day/month/year) 31 OCTOBER 1998
International Patent Classification (IPC) or national classification and IPC IPC(7): C12N 15/85, 15/86; C12N 15/11 and US Cl.: 435/325; 536/23.1		
Applicant UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY		

1.	This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
2.	This REPORT consists of a total of <u>4</u> sheets. <input type="checkbox"/> This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority. (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT). These annexes consist of a total of <u>0</u> sheets.
3.	This report contains indications relating to the following items: <ul style="list-style-type: none"> I <input checked="" type="checkbox"/> Basis of the report II <input type="checkbox"/> Priority III <input type="checkbox"/> Non-establishment of report with regard to novelty, inventive step or industrial applicability IV <input type="checkbox"/> Lack of unity of invention V <input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability, citations and explanations supporting such statement VI <input type="checkbox"/> Certain documents cited VII <input type="checkbox"/> Certain defects in the international application VIII <input type="checkbox"/> Certain observations on the international application

Date of submission of the demand 22 MAY 2000	Date of completion of this report 20 FEBRUARY 2001
Name and mailing address of the IPEA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	Authorized officer JOSEPH T. WOITACH
Facsimile No. (703) 305-3230	Telephone No. (703) 308-0196

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US99/25477

I. Basis of the report**1. With regard to the elements of the international application:***

- ☒ the international application as originally filed
- ☒ the description:
pages 1-35 , as originally filed
pages NONE , filed with the demand
pages NONE , filed with the letter of _____
- ☒ the claims:
pages 36-38 , as originally filed
pages NONE , as amended (together with any statement) under Article 19
pages NONE , filed with the demand
pages NONE , filed with the letter of _____
- ☒ the drawings:
pages 1-6 , as originally filed
pages NONE , filed with the demand
pages NONE , filed with the letter of _____
- ☒ the sequence listing part of the description:
pages NONE , as originally filed
pages NONE , filed with the demand
pages NONE , filed with the letter of _____

2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.
These elements were available or furnished to this Authority in the following language _____ which is:

- ☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in printed form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. ☒ The amendments have resulted in the cancellation of:

- ☒ the description, pages NONE
- ☒ the claims, Nos. NONE
- ☒ the drawings, sheets/fig NONE

5. ☐ This report has been drawn as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**

* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

**Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US99/25477

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**1. statement**

Novelty (N)	Claims	NONE	YES
	Claims	1-19	NO
Inventive Step (IS)	Claims	NONE	YES
	Claims	1-19	NO
Industrial Applicability (IA)	Claims	1-19	YES
	Claims	NONE	NO

2. citations and explanations (Rule 70.7)

Claims 1-19 lack novelty under PCT Article 35(2) as being anticipated by Chen et al. and Tenen et al.

Claims 1-19 encompass a composition of transduced myeloid-committed stem cells and methods of using the composition to express an exogenous genes under the regulation of a myeloid specific promoter in a subject. Several general groups of transgenes are recited in the claims 2, 5, 17 and 19, with specific transgenes associated with diseases/disorders that have defined genetic defects in claims 10-14. The specification describes methodology on how one would isolate the composition of cells and transduce them with retroviral constructs, and general methodology on how one would create the retroviral vectors with the specific transgene and general methodology on how one would treat a subject with a known genetic defect. No details on specific expression levels needed for successful treatment of a specific disease/disorder are discussed. One example of transducing cells with a retroviral vector is given and one prophetic example on how one could potentiate an immune response is described.

Chen et al. describe the isolation of myeloid-committed stem cells (entire document, in particular summarized in abstract and illustrated in figure 3). Further, they demonstrate the retroviral transduction and myeloid specific expression of a transgene in these cells. Finally, Chen et al. propose the use of these cells and other transgenes for the exogenous expression for therapy based treatment of genetic disorders and to potentiate an immune response (page 3216; last paragraph). While Chen et al. do not recite the general list of transgenes or specific transgenes associated with specific disorders/diseases, one of ordinary skill in the art would know how to use and practice the invention as claimed in light of Chen et al., as the transgenes listed in the claims represent genes that one would generally want to express. Therefor, Chen et al. anticipate the claimed invention.

Tenen et al. describe the isolation of the CD11B myeloid specific promoter and methods of using the promoter in vector systems to achieve myeloid specific expression of transgenes in (Continued on Supplemental Sheet.)

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US99/25477

Supplemental Box

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: Boxes I - VIII

Sheet 10

V. 2. REASONED STATEMENTS - CITATIONS AND EXPLANATIONS (Continued):

myeloid cells. As reasoned above for Chen et al., one of ordinary skill in the art would know to use the genes recited in the claims in the expression vectors and methods described in Tenen et al. Therefor, Tenen et al. anticipate the claimed invention.

Persons et al. has been cited to demonstrate another source of a retroviral vector which could be substituted for the one described in Chen et al. or Tenen et al. for use in the methods of cell transduction. Humeau et al. has been cited as alternative source for myeloid progenitor cells. While the specification of the present application teaches methods to isolate a myeloid committed stem cell, claim 1 as written encompasses any composition comprising the myeloid stem cell. Therefor, bone marrow, a source of the myeloid progenitor stem cell, transduced as described by Humeau et al. anticipates claim 1. The general methodology described in the specification of the present application is prophetic and not reduced to practice, and so the prophetic use proposed by Humeau et al. for gene therapy (page 3504; last line) in light of the general reasoning discussed above for one skilled in the art, anticipate claims 2-19.

----- NEW CITATIONS -----

NONE